Publications

Detailed Information

A multicenter phase II study of everolimus in patients with progressive unresectable adenoid cystic carcinoma

DC Field Value Language
dc.contributor.authorKim, Dong-Wan-
dc.contributor.authorOh, Do-Youn-
dc.contributor.authorShin, Seong Hoon-
dc.contributor.authorKang, Jin Hyoung-
dc.contributor.authorCho, Byoung Chul-
dc.contributor.authorChung, Joo-Seop-
dc.contributor.authorKim, HyeJin-
dc.contributor.authorPark, Keon Uk-
dc.contributor.authorKwon, Jung Hye-
dc.contributor.authorHan, Ji-Youn-
dc.contributor.authorKim, Mi-Jung-
dc.contributor.authorBang, Yung-Jue-
dc.date.accessioned2020-04-27T11:24:18Z-
dc.date.available2020-04-27T11:24:18Z-
dc.date.created2020-02-19-
dc.date.created2020-02-19-
dc.date.issued2014-11-
dc.identifier.citationBMC Cancer, Vol.14, p. 795-
dc.identifier.issn1471-2407-
dc.identifier.other91734-
dc.identifier.urihttps://hdl.handle.net/10371/165406-
dc.description.abstractBackground: The aim of this study was to examine the efficacy and safety of everolimus in patients with progressive unresectable adenoid cystic carcinoma (ACC). Methods: Histologically confirmed ACC patients with documented disease progression within 12 months prior to the study entry were eligible. Everolimus was given at a dose of 10 mg daily until progression or occurrence of unacceptable toxicities. The primary endpoint was a 4-month progression-free survival (PFS). Results: A total of 34 patients were enrolled. The 4-month PFS probability was 65.5% (95% one-sided confidence interval [CI], 47.7 to infinity). Median PFS duration was 11.2 months (95% CI, 3.6 to 15.8). Complete or partial response was not achieved. Twenty-seven (79.4%, 95% CI, 63.2 to 89.6) patients showed stable disease (SD). Tumor shrinkage within SD criteria was observed in 15 patients (44.1%) and SD lasting 6 months was observed in 13 patients (38.2%). Four patients had disease progression. Among the 18 patients with both pre- and post-treatment (at 8 weeks) FDG-PET scans available, 8 patients (44.4%) showed a partial metabolic response, defined as a >= 25% reduction in maximum standardized uptake values (SUVmax). The most common adverse events were stomatitis, anemia, asthenia, and leukopenia. No unexpected everolimus related toxicities were reported. Conclusions: Everolimus showed promising efficacy and good tolerability in progressive unresectable ACC.-
dc.language영어-
dc.publisherBioMed Central-
dc.titleA multicenter phase II study of everolimus in patients with progressive unresectable adenoid cystic carcinoma-
dc.typeArticle-
dc.contributor.AlternativeAuthor방영주-
dc.identifier.doi10.1186/1471-2407-14-795-
dc.citation.journaltitleBMC Cancer-
dc.identifier.wosid000344409100001-
dc.identifier.scopusid2-s2.0-84920765637-
dc.citation.startpage795-
dc.citation.volume14-
dc.identifier.sci000344409100001-
dc.description.isOpenAccessY-
dc.contributor.affiliatedAuthorKim, Dong-Wan-
dc.contributor.affiliatedAuthorOh, Do-Youn-
dc.contributor.affiliatedAuthorBang, Yung-Jue-
dc.type.docTypeArticle-
dc.description.journalClass1-
dc.subject.keywordPlusEPIDERMAL-GROWTH-FACTOR-
dc.subject.keywordPlusSALIVARY-GLANDS-
dc.subject.keywordPlusC-KIT-
dc.subject.keywordPlusSOLID TUMORS-
dc.subject.keywordPlusRECURRENT-
dc.subject.keywordPlusMETASTASIS-
dc.subject.keywordPlusIMATINIB-
dc.subject.keywordAuthorAdenoid cystic carcinoma-
dc.subject.keywordAuthorEverolimus-
dc.subject.keywordAuthorRAD001-
dc.subject.keywordAuthorClinical trial-
Appears in Collections:
Files in This Item:
There are no files associated with this item.

Related Researcher

  • College of Medicine
  • Department of Medicine
Research Area Clinical Medicine

Altmetrics

Item View & Download Count

  • mendeley

Items in S-Space are protected by copyright, with all rights reserved, unless otherwise indicated.

Share